1

2

3

4

5

6 7

8

9

10

11

12

13

14

15

16

17

18

19

20 21

22

23

24

25

27

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Running title: Aspirin for COVID-19 **RECOVERY Collaborative Group\*** \*The writing committee and trial steering committee are listed at the end of this manuscript and a complete list of collaborators in the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is provided in the Supplementary Appendix. Correspondence to: Prof Peter W Horby and Prof Martin J Landray, RECOVERY Central Coordinating Office, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, United Kingdom. Email: recoverytrial@ndph.ox.ac.uk Word count: Abstract - 301 words Main text - 3085 words References - 33 Tables & Figures - 2 + 3 26

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

**SUMMARY** 

Background: Aspirin has been proposed as a treatment for COVID-19 on the basis of its antithrombotic properties. **Methods:** In this randomised, controlled, open-label platform trial, several possible treatments were compared with usual care in patients hospitalised with COVID-19. Eligible and consenting adults were randomly allocated in a 1:1 ratio to either usual standard of care plus 150mg aspirin once daily until discharge or usual standard of care alone using web-based simple (unstratified) randomisation with allocation concealment. The primary outcome was 28-day mortality. The trial is registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936). Findings: Between 01 November 2020 and 21 March 2021, 7351 patients were randomly allocated to receive aspirin and 7541 patients to receive usual care alone. Overall, 1222 (17%) patients allocated to aspirin and 1299 (17%) patients allocated to usual care died within 28 days (rate ratio 0.96; 95% confidence interval [CI] 0.89-1.04; p=0.35). Consistent results were seen in all pre-specified subgroups of patients. Patients allocated to aspirin had a slightly shorter duration of hospitalisation (median 8 vs. 9 days) and a higher proportion were discharged from hospital alive within 28 days (75% vs. 74%; rate ratio 1.06; 95% CI 1.02-1.10; p=0.0062). Among those not on invasive mechanical ventilation at baseline, there was no significant difference in the proportion meeting the composite endpoint of invasive mechanical ventilation or death (21% vs. 22%; risk ratio 0.96; 95% CI 0.90-1.03; p=0.23). Aspirin use was associated with an absolute reduction in thrombotic events of 0.6% (SE 0.4%) and an

absolute increase in major bleeding events of 0.6% (SE 0.2%).

- Interpretation: In patients hospitalised with COVID-19, aspirin was not associated
- with reductions in 28-day mortality or in the risk of progressing to invasive mechanical
- ventilation or death but was associated with a small increase in the rate of being
- 54 discharged alive within 28 days.

59

- 55 **Funding:** UK Research and Innovation (Medical Research Council), National Institute
- of Health Research (Grant ref: MC\_PC\_19056), and the Wellcome Trust (Grant Ref:
- 57 222406/Z/20/Z) through the COVID-19 Therapeutics Accelerator.
- 58 **Keywords:** COVID-19, aspirin, clinical trial.

### INTRODUCTION

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

Thrombosis is a key feature of severe COVID-19, with 5-30% of hospitalised patients (depending on illness severity) experiencing a major venous thromboembolic event (mostly pulmonary embolism) and up to 3% an arterial thromboembolic event, particularly myocardial infarction and ischaemic stroke. 1,2 The risk of thromboembolic complications is reported to be higher in COVID-19 than in other acute medical illnesses and viral respiratory infections, and is associated with worse prognosis.<sup>3,4</sup> Antiplatelet therapy may have beneficial effects in severe COVID-19 through several mechanisms including inhibition of platelet aggregation, reduction of platelet-derived inflammation, and blocking thrombogenic neutrophil extracellular traps and disseminated intravascular coagulation.<sup>5</sup> Aspirin is an affordable, globally available drug which at low doses irreversibly inhibits the COX-1 enzyme which is responsible for production of thromboxane A2 and pro-inflammatory prostaglandins. Aspirin can reduce both arterial and venous thrombotic events and has been shown to abolish invitro hyperactivity in platelets from SARS-CoV-2 infected patients.<sup>6,7</sup> Existing randomized evidence has shown that 75-150mg aspirin daily is as effective as higher doses in preventing cardiovascular events.6 Seven clinical trials of aspirin in COVID-19 are registered but none have yet reported on the effect of aspirin therapy in COVID-19. Here we report the results of a large randomised controlled trial of aspirin in patients hospitalised with COVID-19.

### **METHODS**

### Study design and participants

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is an investigator-initiated, individually randomised, controlled, open-label, platform trial to evaluate the effects of potential treatments in patients hospitalised with COVID-19. Details of the trial design and results for other treatments evaluated (lopinavir-ritonavir, hydroxychloroquine, dexamethasone, azithromycin, tocilizumab, convalescent plasma, and colchicine) have been published previously.<sup>8-14</sup> The trial is underway at 177 hospitals in the United Kingdom, two hospitals in Indonesia, and two hospitals in Nepal (appendix pp 5-25), supported in the UK by the National Institute for Health Research Clinical Research Network. The trial is coordinated by the Nuffield Department of Population Health at the University of Oxford (Oxford, UK), the trial sponsor. The trial is conducted in accordance with the principles of the International Conference on Harmonisation–Good Clinical Practice guidelines and approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the Cambridge East Research Ethics Committee (ref: 20/EE/0101). The protocol, statistical analysis plan, and additional information are available on the study website www.recoverytrial.net. Patients admitted to hospital were eligible for the trial if they had clinically suspected or laboratory confirmed SARS-CoV-2 infection and no medical history that might, in the opinion of the attending clinician, put the patient at significant risk if they were to participate in the trial. Children aged <18 years were not eligible for randomisation to aspirin. Patients with known hypersensitivity to aspirin, a recent history of major bleeding, or currently receiving aspirin or another antiplatelet treatment were

excluded. Written informed consent was obtained from all patients, or a legal representative if they were too unwell or unable to provide consent.

# Randomisation and masking

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

Baseline data were collected using a web-based case report form that included demographics, level of respiratory support, major comorbidities, suitability of the study treatment for a particular patient, and treatment availability at the study site (appendix p33-34). Eligible and consenting adult patients were assigned in a 1:1 ratio to either usual standard of care or usual standard of care plus aspirin using web-based simple (unstratified) randomisation with allocation concealed until after randomisation (appendix p30). For some patients, aspirin was unavailable at the hospital at the time of enrolment or was considered by the managing physician to be either definitely indicated or definitely contraindicated. These patients were excluded from the randomised comparison between usual care plus aspirin and usual care alone. Patients allocated to aspirin were to receive 150 mg by mouth (or nasogastric tube) or per rectum daily until discharge. As a platform trial, and in a factorial design, patients could be simultaneously randomised to other treatment groups: i) azithromycin or colchicine or dimethyl fumarate versus usual care, ii) convalescent plasma or monoclonal antibody (REGN-CoV2) versus usual care, and iii) baricitinib versus usual care (appendix pp 30). Until 24 January 2021, the trial also allowed a subsequent randomisation for patients with progressive COVID-19 (evidence of hypoxia and a hyper-inflammatory state) to tocilizumab versus usual care. Participants and local study staff were not masked to the allocated treatment. The trial steering committee, investigators, and all other

individuals involved in the trial were masked to aggregated outcome data during the trial.

#### **Procedures**

A single online follow-up form was completed when participants were discharged, had died or at 28 days after randomisation, whichever occurred earliest (appendix p 35-41). Information was recorded on adherence to allocated study treatment, receipt of other COVID-19 treatments, duration of admission, receipt of respiratory or renal support, and vital status (including cause of death). In addition, in the UK, routine healthcare and registry data were obtained including information on vital status (with date and cause of death), discharge from hospital, receipt of respiratory support, or renal replacement therapy.

### **Outcomes**

Outcomes were assessed at 28 days after randomisation, with further analyses specified at 6 months. The primary outcome was all-cause mortality. Secondary outcomes were time to discharge from hospital, and, among patients not on invasive mechanical ventilation at randomisation, progression to invasive mechanical ventilation (including extra-corporeal membrane oxygenation) or death. Prespecified subsidiary clinical outcomes were use of non-invasive respiratory support, time to successful cessation of invasive mechanical ventilation (defined as cessation of invasive mechanical ventilation within, and survival to, 28 days), use of renal dialysis or haemofiltration, cause-specific mortality, major bleeding events (defined as intracranial bleeding or bleeding requiring transfusion, endoscopy, surgery or vasoactive drugs), thrombotic events (defined as acute pulmonary embolism, deep vein thrombosis, ischaemic stroke, myocardial infarction or systemic arterial

embolism) and major cardiac arrhythmias. Information on suspected serious adverse reactions was collected in an expedited fashion to comply with regulatory requirements.

An intention-to-treat comparison was conducted between patients randomised to

### **Statistical Analysis**

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

aspirin and patients randomised to usual care but for whom aspirin was both available and suitable as a treatment. For the primary outcome of 28-day mortality, the log-rank observed minus expected statistic and its variance were used to both test the null hypothesis of equal survival curves (i.e., the log-rank test) and to calculate the onestep estimate of the average mortality rate ratio. We constructed Kaplan-Meier survival curves to display cumulative mortality over the 28-day period. We used the same method to analyse time to hospital discharge and successful cessation of invasive mechanical ventilation, with patients who died in hospital right-censored on day 29. Median time to discharge was derived from Kaplan-Meier estimates. For the prespecified composite secondary outcome of progression to invasive mechanical ventilation or death within 28 days (among those not receiving invasive mechanical ventilation at randomisation), and the subsidiary clinical outcomes of receipt of ventilation and use of haemodialysis or haemofiltration, the precise dates were not available and so the risk ratio was estimated instead. Prespecified subgroup analyses (defined by characteristics at randomisation: age, sex, ethnicity, level of respiratory support, days since symptom onset, and use of corticosteroids) were performed for the primary outcome using the statistical test of interaction (test for heterogeneity or trend), in accordance with the prespecified analysis plan (appendix p 113). A sensitivity analysis restricting analysis of the primary

outcome to patients with a positive PCR test for SARS-COV-2 was conducted. In addition, post-hoc exploratory analyses of the primary and secondary outcomes by venous thromboprophylaxis treatment at randomisation was conducted. Observed effects within subgroup categories were compared using a chi-squared test for heterogeneity or trend, in accordance with the prespecified analysis plan. Estimates of rate and risk ratios are shown with 95% confidence intervals. All p-values are 2-sided and are shown without adjustment for multiple testing. The full database is held by the study team which collected the data from study sites and performed the analyses at the Nuffield Department of Population Health, University of Oxford (Oxford, UK). As stated in the protocol, appropriate sample sizes could not be estimated when the trial was being planned at the start of the COVID-19 pandemic (appendix p 53). As the trial progressed, the trial steering committee, whose members were unaware of the results of the trial comparisons, determined that sufficient patients should be enrolled to provide at least 90% power at a two-sided significance level of 1% to detect a clinically relevant proportional reduction in 28-day mortality of 12.5% between the two groups. Consequently, on 21 March, 2021, the steering committee, masked to the results, closed recruitment to the aspirin comparison as sufficient patients had been recruited. Analyses were performed using SAS version 9.4 and R version 4.0.3. The trial is registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).

#### Role of the funding source

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

### **RESULTS**

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

Between 1 November 2020 and 21 March 2021, 14892 (66%) of 22560 patients enrolled into the RECOVERY trial were eligible to be randomly allocated to aspirin (i.e. aspirin was available in the hospital at the time and the attending clinician was of the opinion that the patient had no known indication for or contraindication to aspirin, figure 1). 7351 patients were randomly allocated to usual care plus aspirin and 7541 were randomly allocated to usual care alone. The mean age of study participants in this comparison was 59.2 years (SD 14.2) and the median time since symptom onset was 9 days (IQR 6 to 12 days) (webtable 1). At randomisation, 5035 patients (34%) were receiving thromboprophylaxis with higher dose low molecular weight heparin (LMWH), 8878 (60%) with standard dose LMWH, and 979 (7%) were not receiving thromboprophylaxis. The follow-up form was completed for 7290 (99%) participants in the aspirin group and 7457 (99%) participants in the usual care group. Among participants with a completed follow-up form, 6587 (90%) allocated to aspirin received at least one dose and 210 (3%) allocated to usual care received at least one dose of aspirin (figure 1; webtable 2). Of the 6587 participants allocated to aspirin that received at least one dose of aspirin, 5040 (77%) received aspirin on most days following randomisation (≥90% of the days from randomisation to time to discharge or 28 days after randomisation.

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

whichever was earlier). Use of other treatments for COVID-19 was similar among participants allocated aspirin and among those allocated usual care, with nearly 90% receiving a corticosteroid, about one-quarter receiving remdesivir, and one-eighth receiving tocilizumab (webtable 2). Primary and secondary outcome data are known for 99% of randomly assigned patients. We observed no significant difference in the proportion of patients who met the primary outcome of 28-day mortality between the two randomised groups (1222 [17%] patients in the aspirin group vs. 1299 (17%) patients in the usual care group; rate ratio 0.96; 95% confidence interval [CI], 0.89 to 1.04; p=0.35; figure 2, table 2). The rate ratio was similar across all pre-specified sub-groups (figure 3). In an exploratory analysis restricted to the 14467 (97%) patients with a positive SARS-CoV-2 test result, the result was virtually identical (rate ratio 0.96, 95% CI 0.89 to 1.04; p=0.31). Allocation to aspirin was associated with a reduction of 1 day in median time until discharge alive from hospital compared to usual care (median 8 days vs. 9 days [IQR for each 5 to >28 days]) and an increased rate of discharge alive within 28 days (75% vs. 74%, rate ratio 1.06, 95% CI 1.02 to 1.10, p=0.0062) (table 2). Among those not on invasive mechanical ventilation at baseline, the number of patients progressing to the pre-specified composite secondary outcome of invasive mechanical ventilation or death among those allocated to aspirin was similar to that among those allocated to usual care (21% vs. 22%, risk ratio 0.96, 95% CI 0.90 to 1.03, p=0.23). There was no evidence that the effect of allocation to aspirin vs. usual care on time until discharge alive from hospital or on invasive mechanical ventilation or death differed between the pre-specified subgroups of patients (webfigure 1, webfigure 2). In a post-hoc

exploratory analysis there was no evidence that the effect of allocation to aspirin vs. usual care on the primary and secondary outcomes differed by use of LMWH use at randomisation (webfigure 3).

We found no significant differences in the prespecified subsidiary clinical outcomes of cause-specific mortality (webtable 3), use of ventilation, successful cessation of invasive mechanical ventilation, or receipt of renal dialysis or haemofiltration (table 2). As expected with the use of aspirin, the incidence of thrombotic events was lower (4.6% vs. 5.3%; absolute difference 0.6%, SE 0.4%) and the incidence of major bleeding events was higher (1.6% vs. 1.0%; absolute difference 0.6%, SE 0.2%) in the aspirin group (webtable 4). The incidence of new cardiac arrhythmias was similar in the two groups (webtable 5). There were 18 reports of a serious adverse event

believed related to aspirin, all of which were due to haemorrhagic events (webtable 6).

#### DISCUSSION

In this large, randomised trial involving over 14,000 patients and over 2000 deaths, allocation to aspirin was not associated with reductions in mortality or, among those not on invasive mechanical ventilation at baseline, the risk of progressing to the composite endpoint of invasive mechanical ventilation or death. Allocation to aspirin was, however, associated with a small increase in the rate of being discharged from hospital alive within 28 days. These results were consistent across the prespecified subgroups of age, sex, ethnicity, duration of symptoms prior to randomisation, level of respiratory support at randomisation, and use of corticosteroids.

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

As expected, allocation to aspirin was associated with an increased risk of major bleeding and a decreased risk of thromboembolic complications, such that for every 1000 patients treated with aspirin, approximately 6 more would experience a major bleeding event and approximately 6 fewer would experience a thromboembolic event. The rate of reported thromboembolic events in our study population was low (5.3% in the usual care arm) in comparison with previous reports. 1,2 This could be related to the widespread use of corticosteroids in the trial population resulting in reduced thromboinflammatory stimulus or because of the exclusion of patients already receiving aspirin because of prior cardiovascular disease. It is possible that aspirin might have a more meaningful benefit in populations with a higher thrombotic risk, although there would also likely be a corresponding increase in bleeding risk. 15 The pathogenesis of thromboembolism in COVID-19 is likely to be multifactorial. Coagulopathy is common in severe COVID-19 and is associated with an inflammatory state, neutrophil extracellular traps, and poor outcomes.<sup>2,16-20</sup> Platelet activation is increased as a result (and potentially by direct interaction with the virus), amplifying inflammation locally and triggering immunothrombosis. 21,22 In addition, SARS-CoV-2 infection can cause inflammation, dysfunction, and disruption of the vascular endothelium in multiple organs, potentially via direct entry through the ACE-2 receptor.<sup>23-25</sup> The resulting endothelial injury and tissue factor exposure promote thrombosis in the pulmonary circulation and other vascular beds, with microangiopathy and alveolar capillary occlusion contributing to the diffuse alveolar damage and hypoxemia seen in COVID-19.<sup>24,26</sup> Furthermore, in autopsy studies pulmonary microthrombi are nine times more frequent in patients with COVID-19 compared to patients with influenza.24

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

A large number of randomised controlled trials of antithrombotic therapy in COVID-19 are registered, including trials of therapeutic doses of heparin, direct acting oral anticoagulants, anti-platelet agents, serine protease inhibitors, and thrombolytics.<sup>27</sup> In critically-ill patients, the INSPIRATION, REMAP-CAP, ACTIV-4a and ATTACC trials did not report a benefit in clinical outcomes from therapeutic anticoagulation.<sup>28,29</sup> Similarly, preliminary results from the COALIZAO-ACTION trial did not show a benefit from therapeutic anticoagulation (either heparin or rivaroxaban) in a combined endpoint of mortality, successful discharge, or need for oxygen in hospitalised patients D-dimers.<sup>30</sup> with elevated However. the REMAP-CAP/ACTIV-4a/ATTACC investigators have reported that in non-critically ill COVID-19 patients, compared to thromboprophylaxis doses, heparin at therapeutic doses was associated with an absolute increase of 4.6% (95% credible interval 0.7 to 8.1) in the proportion of participants surviving to hospital discharge without receipt of organ support during the first 21 days.31 Although there are currently no other published randomised trial data on the use of aspirin in COVID-19, the REMAP-CAP/ACTIV-4a/ATTACC report does suggest that antithrombotic therapy may be important in some patients.<sup>31</sup> The lack of meaningful benefit from aspirin in our trial could be because antiplatelet therapy confers no significant additional benefit on top of high rates of antithrombotic therapy with LMWH corticosteroid treatment diminishing thrombo-inflammatory and Alternatively, other non-platelet pathways leading to thrombosis and alveolar damage may be more important determinants of clinical outcomes. Any potential benefit of antithrombotic therapies in COVID-19 patients may also depend on timing of treatment initiation, especially if thrombi have already developed

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

by the time of admission.<sup>32</sup> Thromboembolic events and microthrombi are common in COVID-19 patients on either prophylactic or therapeutic anticoagulation.<sup>33</sup> The apparent lack of benefit in INSPIRATION and the REMAP-CAP/ACTIV-4a/ATTACC severe disease cohorts suggests that these patients might have passed the point at which any benefit from the rapeutic anticoagulation could be gained. 28,29 Although we found no evidence of heterogeneity based on duration of symptoms, baseline disease severity, or background thrombotic prophylaxis regimen, ongoing trials of aspirin in ambulatory populations and those exploring more potent anti-platelet inhibition and fibrinolysis should provide further insights. Strengths of this trial included that it was randomised, had a large sample size, broad eligibility criteria, and 99% of patients were followed up for the primary outcome. The trial also had some limitations. Detailed information on radiological or physiological outcomes was not collected. Although this randomised trial is open label (i.e., participants and local hospital staff are aware of the assigned treatment), the primary and secondary outcomes are unambiguous and were ascertained without bias through linkage to routine health records. However, it cannot be excluded that reporting of thromboembolic and bleeding events might have been influenced by knowledge of treatment allocation. Nevertheless, the proportional effects of aspirin on these events were very similar to those reported in previous large clinical trials of aspirin in people with prior cardiovascular disease.6 The RECOVERY trial only studied hospitalised COVID-19 patients and, therefore, is not able to provide evidence on the safety and efficacy of aspirin used in other patient groups. Further studies to identify the safety and efficacy of aspirin in non-hospitalised patients are needed and are ongoing.

In summary, the results of this large, randomised trial do not support the addition of aspirin to standard thromboprophylaxis or therapeutic anticoagulation in patients hospitalised with COVID-19.

### **Contributors**

This manuscript was initially drafted by PWH and MJL, further developed by the Writing Committee, and approved by all members of the trial steering committee. PWH and MJL vouch for the data and analyses, and for the fidelity of this report to the study protocol and data analysis plan. PWH, JKB, MB, LCC, JD, SNF, TJ, EJ, KJ, WSL, AM, AM, KR, GT, MM, RH, and MJL designed the trial and study protocol. MM, MC, G P-A, LP, NB, ST, VC, TB, HT, BE, DC, TW, RS, CG and the Data Linkage team at the RECOVERY Coordinating Centre, and the Health Records and Local Clinical Centre staff listed in the appendix collected the data. NS, ES and JRE did the statistical analysis. All authors contributed to data interpretation and critical review and revision of the manuscript. PWH and MJL had access to the study data and had final responsibility for the decision to submit for publication.

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

Writing Committee (on behalf of the RECOVERY Collaborative Group): Peter W Horby,\* Guilherme Pessoa-Amorim,\* Natalie Staplin,\* Jonathan R Emberson, Mark Campbell, Enti Spata, Leon Peto, Nigel J Brunskill, Simon Tiberi, Victor Chew, Thomas Brown, Hasan Tahir, Beate Ebert, David Chadwick, Tony Whitehouse, Rahuldeb Sarkar, Clive Graham, J Kenneth Baillie, Buddha Basnyat, q Maya H Buch, Lucy C Chappell, Jeremy Day, Saul N Faust, Raph L Hamers, Thomas Jaki, Edmund Juszczak, Katie Jeffery, Wei Shen Lim, Alan Montgomery, Andrew Mumford, Kathryn Rowan, Guy Thwaites, Marion Mafham, † Richard Haynes, \* Martin J Landray. \* \* PWH, GPA and NS made an equal contribution + MM, RH and MJL made an equal contribution **Data Monitoring Committee** Peter Sandercock, Janet Darbyshire, David DeMets, Robert Fowler, David Lalloo, Mohammed Munavvar (from January 2021), Ian Roberts (until December 2020), Janet Wittes. **Declaration of interests** The authors have no conflict of interest or financial relationships relevant to the submitted work to disclose. No form of payment was given to anyone to produce the manuscript. All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. The Nuffield Department of Population Health at the University of Oxford has a staff policy of not accepting honoraria or consultancy fees

directly or indirectly from industry (see <a href="https://www.ndph.ox.ac.uk/files/about/ndph-">https://www.ndph.ox.ac.uk/files/about/ndph-</a>

independence-of-research-policy-jun-20.pdf).

### Data sharing

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

The protocol, consent form, statistical analysis plan, definition & derivation of clinical characteristics & outcomes, training materials, regulatory documents, and other relevant study materials are available online at <a href="https://www.recoverytrial.net">www.recoverytrial.net</a>. As described in the protocol, the trial Steering Committee will facilitate the use of the study data and approval will not be unreasonably withheld. Deidentified participant data will be made available to bona fide researchers registered with an appropriate institution within 3 months of publication. However, the Steering Committee will need to be satisfied that any proposed publication is of high quality, honours the commitments made to the study participants in the consent documentation and ethical approvals, and is compliant with relevant legal and regulatory requirements (e.g. relating to data protection and privacy). The Steering Committee will have the right to review and comment on any draft manuscripts prior to publication. Data will be made available in line with the policy and procedures described at: https://www.ndph.ox.ac.uk/dataaccess. Those wishing to request access should complete the form at https://www.ndph.ox.ac.uk/files/about/data\_access\_enquiry\_form\_13\_6\_2019.docx and e-mail to: data.access@ndph.ox.ac.uk

#### **Acknowledgements**

Above all, we would like to thank the thousands of patients who participated in this trial. We would also like to thank the many doctors, nurses, pharmacists, other allied

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

health professionals, and research administrators at 176 NHS hospital organisations across the whole of the UK, supported by staff at the National Institute of Health Research (NIHR) Clinical Research Network, NHS DigiTrials, Public Health England, Department of Health & Social Care, the Intensive Care National Audit & Research Centre, Public Health Scotland, National Records Service of Scotland, the Secure Anonymised Information Linkage (SAIL) at University of Swansea, and the NHS in England, Scotland, Wales and Northern Ireland. The RECOVERY trial is supported by grants to the University of Oxford from UK Research and Innovation (UKRI)/NIHR (Grant reference: MC\_PC\_19056), the Department of Health and Social Care (DHSC)/UKRI/NIHR COVID-19 Rapid Response Grant (COV19-RECPLA) and the Wellcome Trust (Grant Ref: 222406/Z/20/Z) through the COVID-19 Therapeutics Accelerator. Core funding is provided by NIHR Oxford Biomedical Research Centre, Wellcome, the Bill and Melinda Gates Foundation, the Foreign, Commonwealth and development Department, Health Data Research UK, the Medical Research Council Population Health Research Unit, the NIHR Health Protection Unit in Emerging and Zoonotic Infections, and NIHR Clinical Trials Unit Support Funding. TJ is supported by a grant from UK Medical Research Council (MC UU 00002/14) and an NIHR Senior Research Fellowship (NIHR-SRF-2015-08-001). WSL is supported by core funding provided by NIHR Nottingham Biomedical Research Centre. Combiphar supplied colchicine free of charge for use in this trial in Indonesia. Abbvie contributed some supplies of lopinavir-ritonavir for use in this trial. Tocilizumab was provided free of charge for this trial by Roche Products Limited. REGN-COV2 was provided free of charge for this trial by Regeneron.

The views expressed in this publication are those of the authors and not necessarily those of the NHS or the NIHR.

#### **Conflicts of interest**

The authors have no conflict of interest or financial relationships relevant to the submitted work to disclose. No form of payment was given to anyone to produce the manuscript. All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. The Nuffield Department of Population Health at the University of Oxford has a staff policy of not accepting honoraria or consultancy fees directly or indirectly from industry (see <a href="https://www.ndph.ox.ac.uk/files/about/ndph-independence-of-research-policy-jun-20.pdf">https://www.ndph.ox.ac.uk/files/about/ndph-independence-of-research-policy-jun-20.pdf</a>).

#### References

437

- 438 1. Jimenez D, Garcia-Sanchez A, Rali P, et al. Incidence of VTE and Bleeding
- 439 Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review
- 440 and Meta-analysis. *Chest* 2021; **159**(3): 1182-96.
- 441 2. Kunutsor SK, Laukkanen JA. Incidence of venous and arterial
- thromboembolic complications in COVID-19: A systematic review and meta-analysis.
- 443 Thromb Res 2020; **196**: 27-30.
- 444 3. Klok FA, Kruip M, van der Meer NJM, et al. Confirmation of the high
- cumulative incidence of thrombotic complications in critically ill ICU patients with
- 446 COVID-19: An updated analysis. *Thromb Res* 2020; **191**: 148-50.
- 447 4. Smilowitz NR, Subashchandran V, Yuriditsky E, et al. Thrombosis in
- 448 hospitalized patients with viral respiratory infections versus COVID-19. Am Heart J
- 449 2021; **231**: 93-5.
- 450 5. Carestia A, Davis RP, Grosjean H, Lau MW, Jenne CN. Acetylsalicylic acid
- inhibits intravascular coagulation during Staphylococcus aureus-induced sepsis in
- 452 mice. *Blood* 2020; **135**(15): 1281-6.
- 453 6. Antithrombotic Trialists C. Collaborative meta-analysis of randomised trials of
- antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high
- 455 risk patients. *BMJ* 2002; **324**(7329): 71-86.
- 456 7. Manne BK, Denorme F, Middleton EA, et al. Platelet gene expression and
- 457 function in patients with COVID-19. *Blood* 2020; **136**(11): 1317-29.
- 458 8. RECOVERY Collaborative Group, Horby PW, Mafham M, et al. Lopinavir-
- 459 ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a
- randomised, controlled, open-label, platform trial. Lancet 2020; **396**(10259): 1345-
- 461 52.
- 462 9. RECOVERY Collaborative Group, Horby P, Mafham M, et al. Effect of
- 463 Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med* 2020;
- 464 **383**(21): 2030-40.
- 10. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in
- 466 Hospitalized Patients with Covid-19. *N Engl J Med* 2021; **384**(8): 693-704.
- 467 11. RECOVERY Collaborative Group. Azithromycin in patients admitted to
- hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label,
- 469 platform trial. *Lancet* 2021; **397**(10274): 605-12.
- 470 12. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital
- with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
- 472 *Lancet* 2021; **397**(10285): 1637-45.
- 473 13. RECOVERY Collaborative Group. Convalescent plasma in patients admitted
- 474 to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label,
- 475 platform trial. *Lancet* 2021.

- 476 14. RECOVERY Collaborative Group, Horby PW, Campbell M, et al. Colchicine in
- patients admitted to hospital with COVID-19 (RECOVERY): a randomised.
- 478 controlled, open-label, platform trial. *medRxiv* 2021: 2021.05.18.21257267.
- 479 15. Antithrombotic Trialists C, Baigent C, Blackwell L, et al. Aspirin in the primary
- 480 and secondary prevention of vascular disease; collaborative meta-analysis of
- individual participant data from randomised trials. *Lancet* 2009; **373**(9678): 1849-60.
- 482 16. Jin S, Jin Y, Xu B, Hong J, Yang X. Prevalence and Impact of Coagulation
- 483 Dysfunction in COVID-19 in China: A Meta-Analysis. *Thromb Haemost* 2020;
- 484 **120**(11): 1524-35.
- 485 17. Zhang A, Leng Y, Zhang Y, et al. Meta-analysis of coagulation parameters
- 486 associated with disease severity and poor prognosis of COVID-19. *Int J Infect Dis*
- 487 2020; **100**: 441-8.
- 488 18. Skendros P, Mitsios A, Chrysanthopoulou A, et al. Complement and tissue
- 489 factor-enriched neutrophil extracellular traps are key drivers in COVID-19
- 490 immunothrombosis. *J Clin Invest* 2020; **130**(11): 6151-7.
- 491 19. Middleton EA, He XY, Denorme F, et al. Neutrophil extracellular traps
- contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome.
- 493 *Blood* 2020; **136**(10): 1169-79.
- 494 20. Petito E, Falcinelli E, Paliani U, et al. Association of Neutrophil Activation,
- 495 More Than Platelet Activation, With Thrombotic Complications in Coronavirus
- 496 Disease 2019. *J Infect Dis* 2021; **223**(6): 933-44.
- 497 21. Taus F, Salvagno G, Cane S, et al. Platelets Promote Thromboinflammation
- in SARS-CoV-2 Pneumonia. Arterioscler Thromb Vasc Biol 2020; **40**(12): 2975-89.
- 499 22. Zhang S, Liu Y, Wang X, et al. SARS-CoV-2 binds platelet ACE2 to enhance
- thrombosis in COVID-19. *J Hematol Oncol* 2020; **13**(1): 120.
- 501 23. Hariri LP, North CM, Shih AR, et al. Lung Histopathology in Coronavirus
- 502 Disease 2019 as Compared With Severe Acute Respiratory Sydrome and H1N1
- 503 Influenza: A Systematic Review. *Chest* 2021; **159**(1): 73-84.
- 504 24. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary Vascular
- 505 Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. *N Engl J Med* 2020;
- 506 **383**(2): 120-8.
- 507 25. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and
- 508 endotheliitis in COVID-19. *Lancet* 2020; **395**(10234): 1417-8.
- 509 26. Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a
- series of COVID-19 cases from northern Italy: a two-centre descriptive study. *Lancet*
- 511 Infect Dis 2020.
- 512 27. Talasaz AH, Sadeghipour P, Kakavand H, et al. Recent Randomized Trials of
- Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review.
- 514 *J Am Coll Cardiol* 2021; **77**(15): 1903-21.

- 515 28. Zarychanski R. Therapeutic Anticoagulation in Critically III Patients with Covid-
- 516 19 Preliminary Report. *medRxiv* 2021: 2021.03.10.21252749.
- 517 29. Inspiration Investigators, Sadeghipour P, Talasaz AH, et al. Effect of
- Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic
- 519 Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among
- 520 Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION
- 521 Randomized Clinical Trial. *JAMA* 2021; **325**(16): 1620-30.
- 522 30. R. D. Lopes. AntiCoagulaTlon cOroNavirus ACTION. 2021. AntiCoagulaTlon
- 523 cOroNavirus American College of Cardiology (acc.org) (accessed 22 May 2021
- 524 2021).
- 525 31. Lawler PR, Goligher EC, Berger JS, et al. Therapeutic Anticoagulation in Non-
- 526 Critically III Patients with Covid-19. *medRxiv* 2021: 2021.05.13.21256846.
- 527 32. Yamakawa K, Umemura Y, Murao S, Hayakawa M, Fujimi S. Optimal Timing
- 528 and Early Intervention With Anticoagulant Therapy for Sepsis-Induced Disseminated
- Intravascular Coagulation. *Clin Appl Thromb Hemost* 2019; **25**: 1076029619835055.
- 530 33. Klok FA, Kruip M, van der Meer NJM, et al. Incidence of thrombotic
- complications in critically ill ICU patients with COVID-19. *Thromb Res* 2020; **191**:
- 532 145-7.

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

**Figures** Figure 1: Trial profile ITT=intention to treat. \*Number recruited overall during period that adult participants could be recruited into aspirin comparison. † Includes 379/7351 (5.2%) patients in the aspirin arm and 407/7541 (5.4%) patients in the usual care arm allocated to tocilizumab. Figure 2: Effect of allocation to aspirin on 28-day mortality Figure 3: Effect of allocation to aspirin on 28-day mortality by baseline characteristics Subgroup-specific rate ratio estimates are represented by squares (with areas of the squares proportional to the amount of statistical information) and the lines through them correspond to the 95% Cls. The ethnicity, days since onset and use of corticosteroids subgroups exclude those with missing data, but these patients are included in the overall summary diamond.

### Table 1: Baseline characteristics

551

|  | Treatment allocation     |                        |  |
|--|--------------------------|------------------------|--|
|  | Aspirin (n=7351)         | Usual care<br>(n=7541) |  |
|  | Aspiriii (ii=1331)       | (11=7341)              |  |
| Age, years   | 59.2 (14.1)              | 59.3 (14.3)            |  |
| <70  | 5658 (77%)               | 5786 (77%)             |  |
| ≥70 to <80   | 1163 (16%)               | 1165 (15%)             |  |
| ≥80  | 530 (7%)                 | 590 (8%)               |  |
| Sex  |                          |                        |  |
| Male   | 4570 (62%)               | 4631 (61%)             |  |
| Female*  | 2781 (38%)               | 2910 (39%)             |  |
| Ethnicity  |                          |                        |  |
| White  | 5474 (74%)               | 5655 (75%)             |  |
| Black, Asian, and minority                           | 4470 (400()              | 1000 (100()            |  |
| ethnic   | 1176 (16%)               | 1202 (16%)             |  |
| Unknown  | 701 (10%)                | 684 (9%)               |  |
| Number of days since symptom                         | 9 (7-12)                 | 9 (6-12)               |  |
| niset  | 9 (7-12)                 | 9 (0-12)               |  |
| Number of days since nospitalisation                 | 1 (1-3)                  | 2 (1-3)                |  |
| ioopitalioation                                      | 1 (1 0)                  | 2 (1 0)                |  |
| Respiratory support received                         | 4026 (670/)              | F026 (6 <b>7</b> 9/)   |  |
| None/simple oxygen Non invasive ventilation          | 4936 (67%)<br>2057 (28%) | 5036 (67%)             |  |
| Invasive mechanical                                  | 2037 (20%)               | 2133 (28%)             |  |
| ventilation  | 358 (5%)                 | 372 (5%)               |  |
| Biochemistry   |                          |                        |  |
| C-reactive protein, mg/L                             | 88 (47-146)              | 91 (47-150)            |  |
| Creatinine, umol/L                                   | 76 (63-93)               | 76 (62-92)             |  |
| D-dimer, ng/mL                                       | 475 (205-1088)           | 489 (210-1083          |  |
| Previous diseases                                    |                          |                        |  |
| Diabetes   | 1588 (22%)               | 1659 (22%)             |  |
| Heart disease  | 776 (11%)                | 788 (10%)              |  |
| Chronic lung disease                                 | 1425 (19%)               | 1411 (19%)             |  |
| Tuberculosis   | 20 (<0.5%)               | 21 (<0.5%)             |  |
| HIV  | 25 (<0.5%)               | 21 (<0.5%)             |  |
| Severe liver disease†                                | 67 (1%)                  | 53 (1%)                |  |
| Severe kidney impairment‡                            | 214 (3%)                 | 251 (3%)               |  |
| Any of the above                                     | 3154 (43%)               | 3247 (43%)             |  |
| Jse of corticosteroids                               |                          |                        |  |
| Yes  | 6906 (94%)               | 7109 (94%)             |  |
| No   | 441 (6%)                 | 425 (6%)               |  |
| Missing  | 4 (<0.5%)                | 7 (<0.5%)              |  |
| Severe acute respiratory syndrome coronavirus 2 test |                          |                        |  |
|  |                          |                        |  |
| esult  | 7140 (97%)               | 7327 (97%)             |  |
|  | 7140 (97%)<br>87 (1%)    | 7327 (97%)<br>86 (1%)  |  |

Results are count (%), mean ± standard deviation, or median (inter-quartile range). \*Includes 58 pregnant women. †Defined as requiring ongoing specialist care. ‡Defined as estimated glomerular filtration rate <30 mL/min/1.73m²

# Table 2: Effect of allocation to aspirin on key study outcomes

553


554

555

|   | Treatment allocation |                 |                  |         |
|---|----------------------|-----------------|------------------|---------|
|   | Usual care           |                 |                  |         |
|   | Aspirin (n=7351)     | (n=7541)        | RR (95% CI)      | p value |
| Primary outcome:                              |                      |                 |                  |         |
| 28-day mortality                              | 1222 (17%)           | 1299 (17%)      | 0.96 (0.89-1.04) | 0.35    |
| Secondary outcomes:                           |                      |                 |                  |         |
| Median time to being discharged alive, days   | 8 (5 to >28)         | 9 (5 to >28)    |                  |         |
| Discharged from hospital within 28 days       | 5496 (75%)           | 5548 (74%)      | 1.06 (1.02-1.10) | 0.0062  |
| Receipt of invasive mechanical ventilation or |                      |                 |                  |         |
| death*  | 1473/6993 (21%)      | 1569/7169 (22%) | 0.96 (0.90-1.03) | 0.23    |
| Invasive mechanical ventilation               | 772/6993 (11%)       | 829/7169 (12%)  | 0.95 (0.87-1.05) | 0.32    |
| Death   | 1076/6993 (15%)      | 1141/7169 (16%) | 0.97 (0.90-1.04) | 0.39    |
| Subsidiary clinical outcomes                  |                      |                 |                  |         |
| Use of ventilation                            | 1131/4936 (23%)      | 1198/5036 (24%) | 0.96 (0.90-1.03) | 0.30    |
| Non-invasive ventilation                      | 1101/4936 (22%)      | 1162/5036 (23%) | 0.97 (0.90-1.04) | 0.36    |
| Invasive mechanical ventilation               | 296/4936 (6%)        | 325/5036 (6%)   | 0.93 (0.80-1.08) | 0.35    |
| Successful cessation of invasive mechanical   | . ,                  | . ,             | ,                |         |
| ventilation                                   | 135/358 (38%)        | 135/372 (36%)   | 1.08 (0.85-1.37) | 0.54    |
| Renal replacement therapy                     | 273/7291 (4%)        | 282/7480 (4%)   | 0.99 (0.84-1.17) | 0.93    |

RR=Rate Ratio for the outcomes of 28-day mortality and hospital discharge, and risk ratio for the outcome of receipt of invasive mechanical ventilation or death (and its subcomponents). Cl=confidence interval. \*Analyses exclude those on invasive mechanical ventilation at randomization.

Figure 1: Trial profile



ITT=intention to treat. \*Number recruited overall during period that adult participants could be recruited into aspirin comparison. † Includes 379/7351 (5.2%) patients in the aspirin arm and 407/7541 (5.4%) patients in the usual care arm allocated to tocilizumab.

Figure 2: Effect of allocation to aspirin on 28-day mortality




Figure 3: Effects of allocation to aspirin on 28-day mortality by baseline characteristics

